Restructure Information
On September 15, 2019, Purdue announced a preliminary agreement for settling the massive opioid litigation facing the Company.
To implement this settlement and secure a final resolution of all pending litigation, Purdue and its subsidiaries have voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code.


Adlon Therapeutics logo

Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for ADHD and related disorders. Our initial focus is on adults and adolescents who suffer from symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). Adlon is a subsidiary of Purdue Pharma L.P.

Prescribing Responsibly

Ask Adlon Medical

Adhansia XR™

(Methylphenidate Hydrochloride) Extended-Release Capsules CII

Warning: Abuse and Dependence
CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.